What is HC Wainwright's Estimate for CRBU Q1 Earnings?

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Caribou Biosciences in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst R. Burns forecasts that the company will post earnings per share of ($0.43) for the quarter. HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Caribou Biosciences' Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.54) EPS and FY2025 earnings at ($1.94) EPS.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its quarterly earnings data on Monday, March 10th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.01. The firm had revenue of $2.08 million for the quarter, compared to analyst estimates of $2.11 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%.

Several other equities analysts have also weighed in on CRBU. Bank of America cut their target price on Caribou Biosciences from $13.00 to $11.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. Citigroup reduced their target price on Caribou Biosciences from $30.00 to $6.00 and set a "buy" rating for the company in a report on Tuesday, November 26th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Caribou Biosciences presently has a consensus rating of "Buy" and an average price target of $10.33.

Remove Ads

Caribou Biosciences Stock Performance

Shares of Caribou Biosciences stock traded down $0.06 during midday trading on Friday, reaching $0.96. 1,905,492 shares of the company's stock traded hands, compared to its average volume of 1,594,356. The company has a market cap of $89.32 million, a price-to-earnings ratio of -0.58 and a beta of 2.34. Caribou Biosciences has a 52 week low of $0.95 and a 52 week high of $5.62. The company's 50 day simple moving average is $1.28 and its 200 day simple moving average is $1.73.

Hedge Funds Weigh In On Caribou Biosciences

Several large investors have recently made changes to their positions in CRBU. PFM Health Sciences LP increased its position in Caribou Biosciences by 5.5% in the 3rd quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company's stock worth $8,441,000 after buying an additional 223,299 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Caribou Biosciences by 475.9% in the fourth quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company's stock worth $3,969,000 after acquiring an additional 2,062,563 shares during the last quarter. Schonfeld Strategic Advisors LLC increased its position in Caribou Biosciences by 28.4% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 2,113,272 shares of the company's stock worth $3,360,000 after acquiring an additional 467,738 shares during the period. Geode Capital Management LLC raised its stake in Caribou Biosciences by 6.5% during the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company's stock valued at $3,980,000 after purchasing an additional 124,782 shares during the last quarter. Finally, FMR LLC boosted its holdings in Caribou Biosciences by 7.4% in the 3rd quarter. FMR LLC now owns 1,581,493 shares of the company's stock valued at $3,100,000 after purchasing an additional 109,606 shares during the period. Institutional investors and hedge funds own 77.51% of the company's stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.